L3VLUP
ProSign in

IART in the 13F filings

Integra Lifesciences Holdings Corp · CUSIP 457985208

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2025
the date the book describes
Filed
14 Nov 2025
latest of these filings; the earliest 13 Nov 2025
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q2 2025 and Q3 2025; 2 listed it in both
Shares listed
127,069
combined, among listed positions
Reported value
$1.8m
combined, at the quarter end

Among the 95 comparable managers: 0 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -98,694.

Managers listing IART in Q3 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Winton Group Ltd71,799$1.0munder 0.1%Trimmed-65,75413 Nov 2025 (the filing on sec.gov)
Moore Capital Management LP55,270$792kunder 0.1%Trimmed-32,94014 Nov 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2025 to Q3 2025, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

051015201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
IART by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20131$447kn.a.n.a.
Q3 20132$523kn.a.n.a.
Q4 20131$587kn.a.n.a.
Q1 20152$13mn.a.n.a.
Q2 20152$347mn.a.n.a.
Q3 20155$370mn.a.n.a.
Q4 20153$408mn.a.n.a.
Q1 20164$378mn.a.n.a.
Q2 20165$494mn.a.n.a.
Q3 20164$550mn.a.n.a.
Q4 20168$639mn.a.n.a.
Q1 20179$472mn.a.n.a.
Q2 20176$823mn.a.n.a.
Q3 20175$963mn.a.n.a.
Q4 20173$999mn.a.n.a.
Q1 20183$1.2bnn.a.n.a.
Q2 201810$1.7bnn.a.n.a.
Q3 20186$1.9bnn.a.n.a.
Q4 20187$1.1bnn.a.n.a.
Q1 20198$986mn.a.n.a.
Q2 20197$1.1bnn.a.n.a.
Q3 20195$1.1bnn.a.n.a.
Q4 20195$1.1bnn.a.n.a.
Q1 20207$855mn.a.n.a.
Q2 20205$892mn.a.n.a.
Q3 20206$992mn.a.n.a.
Q4 20206$1.4bnn.a.n.a.
Q1 20214$1.5bnn.a.n.a.
Q2 20216$1.5bnn.a.n.a.
Q3 20216$1.7bnn.a.n.a.
Q4 20216$1.6bnn.a.n.a.
Q1 20228$1.3bnn.a.n.a.
Q2 202210$969mn.a.n.a.
Q3 202214$702mn.a.n.a.
Q4 202211$946mn.a.n.a.
Q1 202311$864mn.a.n.a.
Q2 202312$492mn.a.n.a.
Q3 202313$481mn.a.n.a.
Q4 202310$530m56
Q1 20248$378m72
Q2 20246$212m34
Q3 20243$87m21
Q4 20243$60m22
Q1 20253$34m12
Q2 20252$2.8m12
Q3 20252$1.8m02
Q4 20251$662k1311
Q1 20261$679k1311
Q2 20261$1.8m1412

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

IART and LLY →IART and JNJ →IART and VRTX →Choose a stock to compare with IART →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own IART, latest filings →Back to the 13F Explorer →